Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

Leukemia

Volumn 28, Issue 1, 2014, Pages 230-233

  Le Garff Tavernier, M ^a,b,c   Herbi, L ^a,c,d   De Romeuf, C ^d   Nguyen Khac, F ^b,c,e   Davi, F ^b,c,e   Grelier, A ^b   Boudjoghra, M ^b   Maloum, K ^b   Choquet, S ^a,b,c   Urbain, R ^d   Vieillard, V ^a,c   Merle Beral H ^b,c,e  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Laboratoire Français du Fractionnement et des Biotechnologies   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OBINUTUZUMAB; PROTEIN P53; RITUXIMAB; UBLITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DEGRANULATION; HUMAN; IN VITRO STUDY; LETTER; LEUKEMIA CELL; MONOTHERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE;

EID: 84891868719     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.240     Document Type: Letter

References (15)

1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
2. Catovsky D, Richards S, Matutes E, Oscier D, DyerMJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007; 370: 230-239. (Pubitemid 47069536)
3. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
4. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140: 635-643. (Pubitemid 351300917)
5. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E et al. Analysis of CD16\+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2011; 25: 101-109.
6. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
7. Le Garff-Tavernier M, Blons H, Nguyen-Khac F, Pannetier M, Brissard M, Gueguen S et al. Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J 2011; 1: e5.
8. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458-1461.
9. Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013; 190: 2702-2711.
10. Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295-306.
11. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114: 2589-2597.
12. Cazin B, Lepretre S, Coiffier B, Aurran T, Cartron G, Feugier P et al. Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2011; 118: abstract 2862.
13. Deng C, Effie Amengual J, Schreeder MT, Clark-Garvey S, Patterson M, Miskin H et al. A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients. J Clin Oncol (ASCO Annual Meeting Abstracts) 2013; 31(Suppl): abstract 8575.
14. Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia 2013; 27: 1172-1174.
15. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New Engl J Med 2013; 369: 32-42.